CagriSema combines cagrilintide with semaglutide. The Wegovy injection formulation studied in STEP 1 uses semaglutide alone. The additional ingredient creates a different receptor combination; trial results need to be compared using their populations and statistical analyses.
What the medicines contain
| Formulation | Ingredients | Receptor pathways |
|---|---|---|
| Wegovy injection in STEP 1 | Semaglutide 2.4 mg | GLP-1 |
| CagriSema in REDEFINE 1 | Cagrilintide 2.4 mg plus semaglutide 2.4 mg | Amylin and GLP-1 |
Three published numbers and what they mean
| Study and analysis | Mean weight reduction |
|---|---|
| STEP 1, semaglutide 2.4 mg | 14.9% |
| REDEFINE 1, CagriSema treatment-policy analysis | 20.4% |
| REDEFINE 1, CagriSema if everyone adhered | 22.7% |
STEP 1 and REDEFINE 1 are separate trials. Novo explains the 22.7% adherence estimate. The latter two numbers describe different analyses of REDEFINE 1, rather than conflicting measurements.
Why subtracting the headlines is insufficient
Subtracting 14.9 from 22.7 produces 7.8 percentage points, but that combines separate studies and different analyses. It does not establish that adding cagrilintide produces exactly 7.8 percentage points of extra loss. A within-trial comparison using the same analysis is the appropriate way to estimate the added ingredient's effect.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →What to read alongside the efficacy results
The comparison also needs tolerability, the available formulation, and the evidence for the particular outcome being considered. A larger weight-loss estimate alone does not settle those questions. Our CagriSema side-effects article reports the measured REDEFINE 1 gastrointestinal event rate.
For CagriSema vs Wegovy: The Real Difference Is the Amylin, keep the pharmacy distinction clear: when compounded semaglutide or tirzepatide is prescribed, it is prepared for an individual patient by a licensed 503A compounding pharmacy. Compounded preparations are not FDA-approved drug products and are not interchangeable with Ozempic, Wegovy, Mounjaro, or Zepbound.
FormBlends does not sell or supply CagriSema. CagriSema is investigational. Distribution channels at launch will be determined by Novo Nordisk.
Platform Disclaimer. FormBlends is a telehealth platform that helps connect patients with independent licensed clinicians and pharmacies. We do not manufacture or supply investigational medications including CagriSema. Treatment plans are designed by an independent prescriber based on individual evaluation.
Investigational Drug Notice. CagriSema is under FDA review as of May 2026 and is not commercially available in the United States. Wegovy is FDA-approved and available through standard pharmacy and telehealth channels.
Trademark Notice. Wegovy, Ozempic, Rybelsus, and Saxenda are registered trademarks of Novo Nordisk A/S. CagriSema is a Novo Nordisk development name. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →